Update on primary sclerosing cholangitis
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC) remains one of the most challenging conditions of clinical hepatology. There has been a steady growth in research to overcome this fact and the present review aims at summarizing the most recently published literature. The main emphasis will be put on the link of recent pathogenetic insights to clinical characteristics and patient management. With regard to pathogenesis, there is no consensus yet as to whether immune mediated injury or factors related to bile acid physiology are the most important. It also remains to be clarified whether PSC is a mixed bag of various secondary etiologies yet to be defined, or a disease entity predominantly represented by sclerosing cholangitis in the context of inflammatory bowel disease. Most important, there is no available medical therapy with proven influence on clinical end points, and timing of liver transplantation and patient follow-up are challenging due to the unpredictable and high risk of cholangiocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Self-citationFunctional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · cited 1×
“Importantly, the bile acid pool serves not only as a potential ‘‘toxic medium’’ to epithelial surfaces, but profoundly interacts with the metabolism and immune function via effects on the gut microbiota [56,126,127].”
BackgroundAlvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 1×
“There is growing interest in the influence of this interaction on IBD and liver diseases [128– 130], and it may be wise to advice for future clinical trials in PSC to include assessments of bile acid composition and metagenomic parameters in the basic study readout [51].”
BackgroundSex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity
Markle, J. G. M., Frank, D. N., Mortin-Toth, S., Robertson, C. E., Feazel, L. M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K. D., Macpherson, A. J., & Danska, J. S. (2013) · Science · doi:10.1126/science.1233521 · Cited by 2,025
Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice
Devkota, S., Wang, Y., Musch, M. W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D. A., Jabri, B., & Chang, E. B. (2012) · Nature · doi:10.1038/nature11225 · Cited by 1,904
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628 · cited 1×
“Mechanistically, direct evidence so far available on TGR5 on PSC related aspects seems to concern immunosuppressive effects of receptor activation [32–36], more than aspects of bile homeostasis [17,18,37,38].”
BackgroundRetinoic acid imprints gut-homing specificity on T cells
Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C., & Song, S.-Y. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.011 · Cited by 1,541 · cited 1×
“, a4b7, a4b1, and chemokine C-C motif receptor 9 [CCR9], respectively) is retinoic acid dependent [58], predominantly occurs in the gut associated lymphoid tissues [59], and only under special circumstances in the liver [60].”
BackgroundUnravelling the effects of the environment and host genotype on the gut microbiome
Spor, A., Koren, O., & Ley, R. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2540 · Cited by 1,509
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811 · cited 3×
“There is growing interest in the influence of this interaction on IBD and liver diseases [128– 130], and it may be wise to advice for future clinical trials in PSC to include assessments of bile acid composition and metagenomic parameters in the basic study readout [51].”
BackgroundPSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · cited 2×
“In a position paper published by the International Autoimmune Hepatitis Group (IAIHG), the demarcations between PSC, autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) are elaborated upon [112].”
BackgroundSelf-citationPromise and pitfalls of the Immunochip
Cortes, A., & Brown, M. A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3204 · Cited by 479 · cited 1×
“Genetic risk for PSC was assessed by means of case-control association analysis of a total of 3789 PSC cases to 25,079 controls across 130,422 single-nucleotide polymorphisms (SNPs) genotyped using the Immunochip [10].”
MethodNatural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Expression and function of the bile acid receptor TGR5 in Kupffer cells
Keitel, V., Donner, M., Winandy, S., Kubitz, R., & Häussinger, D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.171 · Cited by 418 · cited 1×
“Mechanistically, direct evidence so far available on TGR5 on PSC related aspects seems to concern immunosuppressive effects of receptor activation [32–36], more than aspects of bile homeostasis [17,18,37,38].”
BackgroundDrug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“These chloride ions are exchanged for bicarbonate by the anionic exchanger 2 (AE2) molecule, and the bicarbonate may constitute one of the mechanisms by which the biliary epithelium is protected against toxic effects frombile [51].”
BackgroundTischendorf, J. J. W., Hecker, H., Krüger, M., Manns, M. P., & Meier, P. N. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00872.x · Cited by 413
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Self-citationCharatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393 · cited 1×
“As is the case for conventional brush cytology, specificity of FISH is generally good, whereas the reported sensitivity varies between investigators and study populations in the range of 50% and 87% [101,102].”
BackgroundThe UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2616 · Cited by 391
Self-citationCipriani, S., Mencarelli, A., Chini, M. G., Distrutti, E., Renga, B., Bifulco, G., Baldelli, F., Donini, A., & Fiorucci, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025637 · Cited by 382 · cited 1×
“Mechanistically, direct evidence so far available on TGR5 on PSC related aspects seems to concern immunosuppressive effects of receptor activation [32–36], more than aspects of bile homeostasis [17,18,37,38].”
BackgroundFluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma
Anderson, C. D., Rice, M. H., Pinson, C. W., Chapman, W. C., Chari, R. S., & Delbeke, D. (2004) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2003.10.003 · Cited by 377
Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355 · cited 2×
“The hepatoyte initiates a variety of detoxificationmechanisms in cholestasis, ncluding hydroxylation and conjugation to make bile acids more ater soluble and induction of bile acid transporters on the sinuoidal membrane leading to export of metabolized bile acids to the ystemic circulation for renal elimination [89].”
BackgroundBeuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology · doi:10.1002/hep.23810 · Cited by 351 · cited 1×
“, loss of alkalization of cholangiocyte apical membrane proximity) may increase membrane permeation of protonated (and thus hydrophobic) bile acids leading to bile duct injury [14].”
BackgroundA preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
Mitchell, S. A., Bansi, D. S., Hunt, N., Bergmann, K. V., Fleming, K. A., & Chapman, R. W. (2001) · Gastroenterology · doi:10.1053/gast.2001.27965 · Cited by 351
Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315
Guo, G. L., Lambert, G., Negishi, M., Ward, J. M., Brewer, H. B., Kliewer, S. A., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307145200 · Cited by 312 · cited 1×
“One of the major eterminants of the expression of the genes involved in these rocesses is the steroid and xenobiotic receptor (SXR; also called regnane X receptor, PXR) [90,91].”
BackgroundThe natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305
Self-citationAlabraba, E., Nightingale, P., Gunson, B., Hubscher, S., Olliff, S., Mirza, D., & Neuberger, J. (2009) · Liver Transplantation · doi:10.1002/lt.21679 · Cited by 298 · cited 1×
“One key ongoing discussion relates to whether the presence of an intact colon in PSC patients with IBD influences disease recurrence, but due to the lack of reproduction so far [148], these data are only useful for pathophysiological considerations and should not prompt pre-transplantation colectomy on a general basis.”
BackgroundModica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Sclerosing cholangitis: a focus on secondary causes
Abdalian, R., & Heathcote, J. E. (2006) · Hepatology · doi:10.1002/hep.21405 · Cited by 230 · cited 1×
“ince the biliary tract exhibits a limited repertoire for reacting to ny insult, a variety of pathogenetic mechanisms may give rise o a clinical presentation of sclerosing cholangitis [32].”
BackgroundFärkkilä, M., Karvonen, A., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., & Kärkkäinen, P. (2004) · Hepatology · doi:10.1002/hep.20457 · Cited by 218 · cited 1×
“Regarding absorbable antibiotics, improvements in hepatic biochemistries have also been observed for metronidazole [132], azithromycin [133] and minocycline [134], altogether suggesting that liver affection in PSC may be influenced by antimicrobial therapies.”
BackgroundSmall-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis
Kaya, M., Petersen, B. T., Angulo, P., Baron, T. H., Andrews, J. C., Gostout, C. J., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03690.x · Cited by 196
Gallbladder disease in patients with primary sclerosing cholangitis
Said, K., Glaumann, H., & Bergquist, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.019 · Cited by 193 · cited 1×
“The importance of considering also the gallbladder epithelium at increased risk of malignancies in PSC is now established [91,92], but there is not yet consensus as to what size of lesions should trigger cholecystectomy [93,94].”
BackgroundKaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Bergquist, A., Montgomery, S. M., Bahmanyar, S., Olsson, R., Danielsson, Å., Lindgren, S., Prytz, H., Hultcrantz, R., Lööf, L., Sandberg–Gertzén, H., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.016 · Cited by 188
Autoantibodies in primary sclerosing cholangitis
Hov, J. R., Boberg, K. M., & Karlsen, T. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3781 · Cited by 187
Self-citationRecurrence and rejection in liver transplantation for primary sclerosing cholangitis
Fosby, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.1 · Cited by 175 · cited 1×
“The present literature on the high risk of acute cellular rejections in PSC following liver transplantation and PSC recurrence in the allograft was recently reviewed elsewhere [147].”
BackgroundDiagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis
Boberg, K. M., Jebsen, P., Clausen, O. P., Foss, A., Aabakken, L., & Schrumpf, E. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.010 · Cited by 159
Self-citationRudolph, G., Gotthardt, D., Klöters-Plachky, P., Kulaksiz, H., Rost, D., & Stiehl, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.023 · Cited by 156 · cited 2×
“The presence of dominant stricures was also recently reported to associate with poor outcome in SC [6].”
BackgroundSinakos, E., Saenger, A. K., Keach, J., Kim, W. R., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.007 · Cited by 142 · cited 1×
“The difficulties associated with the detection of increased levels of CA19-9 outside the context of malignancy emphasize that all assessments for cholangiocarcinoma in PSC need to be multimodal [95,96].”
BackgroundCullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136
Broomé, U., Glaumann, H., Lindstöm, E., Lööf, L., Almer, S., Prytz, H., Sandberg-Gertzén, H., Lindgren, S., Fork, F.-T., Järnerot, G., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00036-3 · Cited by 131
Keitel, V., Ullmer, C., & Häussinger, D. (2010) · Biological Chemistry · doi:10.1515/bc.2010.077 · Cited by 129
Lewis, J. T., Talwalkar, J. A., Rosen, C. B., Smyrk, T. C., & Abraham, S. C. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181bc96f9 · Cited by 122 · cited 1×
“, dominant strictures) is controversial since up to 1/3 of PSC patients may show such features [98,104,105].”
BackgroundMoff, S. L., Kamel, I. R., Eustace, J., Lawler, L. P., Kantsevoy, S., Kalloo, A. N., & Thuluvath, P. J. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.12.034 · Cited by 98
Late acute rejection after liver transplantation impacts patient survival
Uemura, T., Ikegami, T., Sanchez, E. Q., Jennings, L. W., Narasimhan, G., McKenna, G. J., Randall, H. B., Chinnakotla, S., Levy, M. F., Goldstein, R. M., et al. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00788.x · Cited by 91
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis
Goldberg, D. S., Camp, A., Martinez-Camacho, A., Forman, L., Fortune, B., & Reddy, R. K. (2013) · Liver Transplantation · doi:10.1002/lt.23587 · Cited by 58
Neumann, K., Kruse, N., Szilagyi, B., Erben, U., Rudolph, C., Flach, A., Zeitz, M., Hamann, A., & Klugewitz, K. (2012) · Hepatology · doi:10.1002/hep.24816 · Cited by 39 · cited 1×
“, a4b7, a4b1, and chemokine C-C motif receptor 9 [CCR9], respectively) is retinoic acid dependent [58], predominantly occurs in the gut associated lymphoid tissues [59], and only under special circumstances in the liver [60].”
Background
Cited by
The International IBD Genetics Consortium (IIBDGC), Ellinghaus, D., International Genetics of Ankylosing Spondylitis Consortium (IGAS), International PSC Study Group (IPSCSG), Genetic Analysis of Psoriasis Consortium (GAPC), Psoriasis Association Genetics Extension (PAGE), Jostins, L., Spain, S. L., Cortes, A., Bethune, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3528 · Cited by 751
Self-citationNakamoto, N., Sasaki, N., Aoki, R., Miyamoto, K., Suda, W., Teratani, T., Suzuki, T., Koda, Y., Chu, P.-S., Taniki, N., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0333-1 · Cited by 425
Chronic ulcerative colitis and colorectal cancer
Rogler, G. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.07.032 · Cited by 413
Molecular Pathogenesis of Cholangiocarcinoma
Labib, P. L., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 310
Arbelaiz, A., Azkargorta, M., Krawczyk, M., Santos‐Laso, A., Lapitz, A., Perugorria, M. J., Erice, O., Gonzalez, E., Jimenez‐Agüero, R., Lacasta, A., et al. (2017) · Hepatology · doi:10.1002/hep.29291 · Cited by 289
Metadata
- Authors
- Karlsen, T. H., & Boberg, K. M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 59
- Issue
- 3
- Pages
- 571-582
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2002621738
- Cited by
- 122
- References
- 64
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.